Vidyasiri Vemulapalli

Vidyasiri Vemulapalli is a Senior Scientist I at Revolution Medicines since October 2021, with a strong background in cancer research and molecular biology. Previous roles include Scientist at Dana-Farber Cancer Institute, where Vidyasiri contributed to key publications through collaboration with Novartis Institutes for Biomedical Research on SHP2 inhibitors, and serving as a Postdoctoral Researcher. Prior experience includes positions at MD Anderson Cancer Center, focusing on translational collaborations and project management in mass spectrometry, and conducting high-content phenotypic screenings at The University of Texas at San Antonio. Educational qualifications include a PhD in Epigenetics and Molecular Carcinogenesis from UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, an MS in Biology from The University of Texas at San Antonio, and a B.Tech in Biotechnology from Vellore Institute of Technology.